Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy ...
Dr Radha Sundaram says she was 'slowly going blind' before she received the 'life-changing' cornea transplant.
CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback